Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer’s disease
暂无分享,去创建一个
C. Mummery | L. Mignon | D. Norris | R. Lane | H. Kordasiewicz | T. Baumann | K. Moore | Danielle L. Graham | Candice E. Junge | R. Crean | E. Ratti | Chris Yun | Dan Li | E. Huang